A long-lasting universal flu vaccine
For decades, researchers have been doggedly pursuing a universal flu vaccine--one that would protect against the evolving influenza virus for years rather than just a single season--with little success. The bug mutates so quickly that a new vaccine must be specially formulated each year. But a relatively new strategy, targeting a rarely seen portion of the virus, is now showing some success.
A novel vaccine developed by microbiologist Peter Palese and collaborators at Mount Sinai School of Medicine in New York showed protective effects in rodents against three different flu strains, with protection ranging from mild (against hemagglutinin 1, such as that of the H1N1 or "swine" flu) to middling (against the avian flu H5 subtype) to absolute (against the common H3 flu subtype). While the results are far from perfect, the proof-of-principle demonstrates the potential for a universal flu vaccine.
- How Top-Ranked MA Plans Earn Their Stars
- How Hospitals Can Become 'Upstreamists'
- Readmissions: No Quick Fix to Costly Hospital Challenge
- WellPoint Dominates Nearly Half of Markets, AMA Says
- 4 Ways to Lower the Cost to Collect from Self-Pay Patients
- CMS Offers Some ACOs $114M for 'Upfront' Costs
- 4 Tips for Managing Employed Physicians
- House Calls Key to Pioneer ACO Success
- Ebola: Second TX Nurse Diagnosed After Improper Protective Gear Application
- Providers Ask HHS to Address EHR Interoperability Barriers